- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02409381
Extract of Curcuma Longa Complexed With Phosphatidilcholine(Motore®)in the Treatment of Adults With Knee Osteoarthritis
August 24, 2016 updated by: Ache Laboratorios Farmaceuticos S.A.
Clinical Trial, Multicenter, Phase IV, Open, Randomized, Parallel, Controlled, Non-inferiority, to Evaluate the Efficacy and Safety of Motore® Compared to Alivium® in the Treatment of Adults With Knee Osteoarthritis
Prospective, multicenter, phase IV, open, randomized, parallel, controlled, in which 288 (two hundred and eighty-eight) participants of both sexes, aged between 40 and 75 years will be randomly allocated to one of two treatment groups , and treatment group 01 will be the dried extract of Curcuma longa complexed with phosphatidylcholine (Motore®), and treatment group 02 will ibuprofen (Alivium®).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study evaluate the efficacy and safety of Dry Extract of Curcuma Longa complexed with phosphatidilcholine (Motore®) Compared to Ibuprofen (Alivium® ) in the treatment of adults with knee osteoarthritis.
The study population will consist in participants of both sexes, aged between 40 and 80 years old with a clinical diagnosis of knee osteoarthritis (tibiofemoral joint) based on clinical and radiological criteria (Grades 2 and 3 Kellgren and Lawrence) and who had osteoarthritis symptoms in the last six (06) months preceding the start of the study.
They will be randomly allocated to one of two treatment groups , and treatment group 01 will be the dried extract of Curcuma longa complexed with phosphatidylcholine (Motore®), and treatment group 02 will ibuprofen (Alivium®).
Study Type
Interventional
Enrollment (Actual)
288
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Guarulhos, São Paulo, Brazil
- Ache Laboratorios Farmaceuticos
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants of both sexes;
- Age greater than or equal to 40 years and less than or equal to 75 years;
- Clinical diagnosis of osteoarthritis of the knee (tibiofemoral joint) based on clinical and radiological criteria (Grade 2 and 3 Kellgren and Lawrence) as specified below:
- Pain on movement in the affected knee on most days of the last month, with at least partial relief at rest;
- Presence of osteophytes of at least 1 mm in radiological imaging, a report issued by a qualified professional from the center;
- Symptoms of osteoarthritis in the last 06 months preceding the start of the study;
- Visual Analogue Scale with 40mm or greater value (considering the data obtained at the randomization visit);
- Ability to understand and consent to participate in this clinical study, manifested by signing the Informed Consent Form (ICF).
Exclusion Criteria:
- Any finding of clinical observation (clinical and physical examination) or laboratory finding that is interpreted by the researcher as a medical risk to participation in the clinical trial;
- Any finding of ECG examination the investigator physician considers risk as to the research participant about their participation in the clinical trial;
- Known hypersensitivity to the components of the medications used during the study;
- Women in pregnancy or nursing period;
- in premenopausal women who do not agree to use acceptable contraceptive methods (oral contraceptives, injectable contraceptives, hormonal implants, barrier methods, abstinence, hormonal patch and tubal ligation); except surgically sterile (bilateral oophorectomy or hysterectomy);
- concomitant arthropathy that may confuse or interfere with pain assessment or efficacy, including: inflammatory arthropathy (rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatic), gouty arthritis, acute episodes of monoarthritis compatible with pseudogout, Paget's disease with involvement of the joint study, history of septic arthritis, avascular necrosis or intra-articular joint studied, Wilson's disease, hemochromatosis, alkaptonuria, primary osteochondromatosis fracture;
- Infectious Arthritis as gonococcal and syphilitic;
- History of significant collateral ligament injury, or anterior cruciate, or the meniscus of the joint study, requiring surgery or immobilization for more than three weeks (minor ligament injuries, six months prior to the study, are not exclusion criteria );
- History of arthroscopy of the affected knee during the six months preceding the entry of the research participant in the study;
- History of any illness that, in the opinion of the investigator, might confound the results of the study or research participant put on additional risk;
- Treatment with corticosteroids as follows:
- Use of corticosteroids orally or intramuscularly for one month prior to the randomization visit (V0);
- Administration of intra-articular corticosteroid, the joint study in the previous three months at randomization visit (V0);
- Administration of intra-articular corticosteroids in any joint a visit prior to randomization (V0) month;
- intra-articular injection of hyaluronic acid in the joint or congeners studied in the last twelve months prior to randomization visit (V0);
- Implementation of any other medical treatment for osteoarthritis in the pre-randomization visit (V0) months;
- Body Mass Index (BMI) equal to or greater than 35;
- Participant that is in use Prohibited Drug;
- the presence of serious psychiatric illness of any kind that prevents the proper performance of study-related procedures and good adherence to treatment;
- Participant that has some relation to the second degree of kinship or relationship with employees or employees of Sponsor and Research Center.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Motore
Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours
|
250 mg
Other Names:
|
Active Comparator: Alivium
Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.
|
600 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in the pain domain score of the WOMAC questionnaire
Time Frame: After 42 (forty two) days of treatment
|
The primary efficacy endpoint will be the reduction in the pain domain score of the WOMAC questionnaire after 42 (forty two) days of treatment
|
After 42 (forty two) days of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Francisco Rocha, MD, Artroclinica de Fortaleza
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
April 1, 2015
First Submitted That Met QC Criteria
April 3, 2015
First Posted (Estimate)
April 6, 2015
Study Record Updates
Last Update Posted (Estimate)
August 25, 2016
Last Update Submitted That Met QC Criteria
August 24, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACH-MTR-04(02/13)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on Motore
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Fondazione Don Carlo Gnocchi OnlusCompleted